As of May 29, 2025, Kiadis Pharma NV (KDS.AS) reports a Net Margin of -468.23%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Comparing Kiadis Pharma NV's Net Margin to Peers
To better understand Kiadis Pharma NV's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Kiadis Pharma NV (KDS.AS) | -468.23% |
| Bioventix PLC (BVXP.L) | 59.51% |
| Saniona AB (SANION.ST) | 56.39% |
| OSE Immunotherapeutics SA (OSE.PA) | 44.88% |
| argenx SE (ARGX.BR) | 38.03% |
| Mabion SA (MAB.WA) | 27.21% |
Compared to its competitors, Kiadis Pharma NV's Net Margin is about average compared to peers, reflecting typical industry profitability.